Literature DB >> 34761363

Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults.

Alicia Danforth1.   

Abstract

Access to the Internet has upended long-standing myths and misconceptions about autism as autistic individuals are enabled through technology increasingly to influence the dialog around neurodiversity, the experience of being autistic, and the effectiveness of mental health interventions for autistic adults. Autistic self-advocates are speaking up in support of including neurodivergent adults as a population that might benefit from the burgeoning psychedelic medicine field, in an absence of many other mental health treatment options that have been researched and shown to be effective for them. Autism is a genetically-determined neurocognitive variant with considerable heterogeneity across the broad autistic phenotype spectrum. Therefore, enthusiasm for investigating psychedelics to cure or alter the course of autism is most likely ill-informed and misdirected; psychiatric and psychopharmacological interventions do not alter the genome. However, autism frequently co-occurs with clinical conditions such as anxiety, depression, obsessive-compulsive disorder, and trauma that have been investigated as indications for clinical trials with classic and atypical psychedelics. The purpose of this chapter will be to inform researchers and clinicians on the history of clinical research with classic psychedelics with autistic minors, recent and current clinical trials of atypical psychedelics with autistic adults, and considerations for providing psychedelic-assisted psychotherapies that are compatible with autism.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Asperger’s; Autism; MDMA; Psychedelics; Social anxiety

Mesh:

Substances:

Year:  2022        PMID: 34761363     DOI: 10.1007/7854_2021_269

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  34 in total

1.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

2.  MDMA enhances pleasantness of affective touch.

Authors:  Harriet de Wit; Anya K Bershad
Journal:  Neuropsychopharmacology       Date:  2019-08-07       Impact factor: 7.853

Review 3.  The us of LSD (d-lysergic acid diethylamide) in the therapy of children (a brief review).

Authors:  H A Abramson
Journal:  J Asthma Res       Date:  1967-12

4.  Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults.

Authors:  Alicia L Danforth
Journal:  J Psychoactive Drugs       Date:  2019-03-25

5.  A meta-analysis of sensory modulation symptoms in individuals with autism spectrum disorders.

Authors:  Ayelet Ben-Sasson; Liat Hen; Ronen Fluss; Sharon A Cermak; Batya Engel-Yeger; Eynat Gal
Journal:  J Autism Dev Disord       Date:  2008-05-30

6.  Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Alicia L Danforth; Charles S Grob; Christopher Struble; Allison A Feduccia; Nick Walker; Lisa Jerome; Berra Yazar-Klosinski; Amy Emerson
Journal:  Psychopharmacology (Berl)       Date:  2018-09-08       Impact factor: 4.530

7.  Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey.

Authors:  Devon M Coleman; James B Adams; Amy L Anderson; Richard E Frye
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-02-06       Impact factor: 2.576

8.  Making sense of the perceptual capacities in autistic and non-autistic adults.

Authors:  Jana Brinkert; Anna Remington
Journal:  Autism       Date:  2020-05-31

9.  Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.

Authors:  Danilo De Gregorio; Jelena Popic; Justine P Enns; Antonio Inserra; Agnieszka Skalecka; Athanasios Markopoulos; Luca Posa; Martha Lopez-Canul; He Qianzi; Christopher K Lafferty; Jonathan P Britt; Stefano Comai; Argel Aguilar-Valles; Nahum Sonenberg; Gabriella Gobbi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

10.  LSD enhances suggestibility in healthy volunteers.

Authors:  R L Carhart-Harris; M Kaelen; M G Whalley; M Bolstridge; A Feilding; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2014-09-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.